15 completed, 12 unknown, 6 terminated, 4 withdrawn. 43 Phase 2, 12 Phase 3, 4 Phase 1.
Follow Ursodeoxycholic Acid: new trials by email Literature Review of Ursodeoxycholic Acid trials Research Report on Ursodeoxycholic Acid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Adjunctive Ursodeoxycholic Acid on Oxidative Stress, Inflammation, and Organ Dysfunction in Adults With Sepsis Standard medical treatment, Ursodeoxycholic Acid - Sepsis | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 80 | 2026-10-01 | 2026-10-07 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis UDCA (Ursodeoxycholic acid), Corticosteroids (Reference Treatment) - Immune-Mediated Cholestasis | Phase 2 | Recruiting | University Hospital, Montpellier | 94 | 2026-06-25 | 2026-09-09 |
| Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors UDCA (Ursodeoxycholic acid), Placebo - Kidney Cancer | Phase 2 | Recruiting | Jinling Hospital, China | 162 | 2026-06-01 | 2026-10-15 |
| PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer Ursodeoxycholic Acid (URSO), Radiotherapy, Adebrelimab (PD-L1 inhibitor) - Breast Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 70 | 2025-02-01 | 2025-02-24 |
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics Prednisone, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 2 / Phase 3 | Enrolling by invitation | Han Ying | 244 | 2024-10-30 | 2026-10-29 |
| Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus Ursodeoxycholic acid - Diabetes Mellitus, Type 2 | Phase 2 / Phase 3 | Unknown | Tanta University | 88 | 2023-06-28 | 2023-06-15 |
| Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis Placebo, Ursodeoxycholic acid (UDCA) 500 mg - Rheumatoid Arthritis | Phase 2 | Completed | Tanta University | 60 | 2023-05-01 | 2024-06-03 |
| A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide - Hepatitis D | Phase 2 | Unknown | National Taiwan University Hospital | 30 | 2023-02-24 | 2022-12-29 |
| BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases 4-Phenylbutyrate - Hereditary Diseases, Cholestasis, Intrahepatic | Phase 2 / Phase 3 | Withdrawn | Children's Hospital of Fudan University | 2023-02-08 | 2023-02-09 | |
| The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19) Ursodeoxycholic acid - COVID-19 | Phase 1 / Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 95 | 2022-12-16 | 2025-02-24 |
| Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis Placebo, Digoxin 0.25 mg, Ursodeoxycholic acid (UDCA) 500 mg - Rheumatoid Arthritis | Phase 2 | Completed | Tanta University | 90 | 2021-11-01 | 2023-03-22 |
| Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children Pancreatic Enzyme, Ursodeoxycholic acid, Pancreatic Enzyme placebo - SEPSIS, MALNUTRITION, CHILD | Phase 2 / Phase 3 | Unknown | University of Oxford | 400 | 2021-07-01 | 2023-02-24 |
| Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid - Hepatitis, Drug-Induced | Phase 2 | Unknown | Inge Marie Svane | 60 | 2021-04-07 | 2022-12-14 |
| A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) HTD1801, Ursodeoxycholic Acid - Primary Sclerosing Cholangitis, Cholangitis | Phase 2 | Withdrawn | HighTide Therapeutics (Hong Kong) Limited | 2021-03-01 | 2026-08-12 | |
| Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin UDCA - Diabetes Mellitus | Phase 2 / Phase 3 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 1000 | 2021-03-01 | 2022-09-28 |
| Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients efficacy and safety of CNU® Capsule - Dyspepsia, Biliary Dysplasia | Phase 1 / Phase 2 | Completed | Gangnam Severance Hospital | 37 | 2019-11-01 | 2022-03-22 |
| The Role of Secondary Bile Acids in Intestinal Inflammation ursodiol (ursodeoxycholic acid, UDCA) - Ulcerative Colitis, Pouchitis | Phase 2 / Phase 3 | Terminated | Stanford University | 2 | 2019-08-26 | 2026-03-11 |
| Metformin in Intrahepatic Cholestasis of Pregnancy Metformin, Ursodeoxycholic Acid - Intrahepatic Cholestases, Pregnancy Complications | Phase 2 / Phase 3 | Unknown | Epsom and St Helier University Hospitals NHS Trust | 40 | 2019-01-01 | 2018-07-26 |
| Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis Ursodeoxycholic Acid - Hepatic Sarcoidosis, Elevated Alkaline Phosphatase | Phase 2 | Terminated | Ethan Weinberg | 7 | 2018-08-20 | 2023-06-07 |
Showing 20 of 43. Sign in to see all of them.
Liver Cirrhosis, Biliary (5) · Cholestasis (3) · Cholestasis, Intrahepatic (3) · Digestive System Diseases (3) · Genetic Diseases, Inborn (3) · Liver Diseases (3) · Adenoma (2) · Adenomatous Polyposis Coli (2) · Arthritis, Rheumatoid (2) · Cholangitis, Sclerosing (2) · Colorectal Neoplasms (2) · Diabetes Mellitus, Type 2 (2) · Gastrointestinal Diseases (2) · Neoplasms (2) · Sepsis (2)
Tanta University (4) · Radboud University Medical Center (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing 302 Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Hospital of Fudan University (1) · Epsom and St Helier University Hospitals NHS Trust (1) · Ethan Weinberg (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · Gangnam Severance Hospital (1) · GlaxoSmithKline (1) · Gregory Graf, PhD (1) · Han Ying (1) · HighTide Therapeutics (Hong Kong) Limited (1)
United States (11) · China (8) · Egypt (4) · United Kingdom (4) · Canada (3) · France (3) · Netherlands (3) · Germany (2) · Spain (2) · Austria (1) · Bangladesh (1) · Denmark (1) · Italy (1) · Kenya (1) · Malawi (1)
Enass Yousef Osman, PHD (2) · Mariam George Tadros Bolous, Master (2) · Medhat Ismail Abdel Hamid, Professor (2) · Nageh Ahmed El-Mahdy, Professor (2) · Alberto Albanese, MD (1) · Bhaskar Banerjee (1) · Bjorn WH van Heumen, MD (1) · Charlie Xiang, Professor (1) · Cynthia Blanco, M.D. (1) · Dalia Salah Seif, Associate Professor (1) · Dalia Salah Seif, PHD (1) · David A Shapiro, MD (1) · Ellen Kampman, Ph D (1) · Enver H Fekaj, PhD student (1)
PMID 19585548, PMID 21608000, PMID 21899713, PMID 22300693, PMID 23919274, PMID 24053627, PMID 24245549, PMID 24942592, PMID 25393877, PMID 25445618, PMID 25500425, PMID 25664595, PMID 26659833, PMID 26977164, PMID 27212247, PMID 27431238, PMID 27824743, PMID 28187915, PMID 32344198, PMID 32716060, PMID 38780109, PMID 39498340, PMID 41786454, PMID 42643234
2008 (1), 2025 (1), N01CN35158 (1), P30CA016672 (1), P30CA023074 (1), P50CA095060 (1), R01DK056924 (1)